Article Sidebar

PDF (Tiếng Việt)
Published: 2025-09-30
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v194i9.3886
Issue
Vol. 194 No. 9 (2025)
Section
Các bài báo
How to Cite
Hằng, P. T., Châu, T. T. B., & Trinh, N. T. N. (2025). 40. Effectiveness of estradiol and progesterone therapy on hot flashes in perimenopausal and postmenopausal women: A before-after study. Journal of Medical Research, 194(9), 401-415. https://doi.org/10.52852/tcncyh.v194i9.3886

40. Effectiveness of estradiol and progesterone therapy on hot flashes in perimenopausal and postmenopausal women: A before-after study

Phan Thi Hang, Tran Thi Bao Chau, Nguyen Thi Ngoc Trinh

Main Article Content

Abstract

Hot flashes are common and distressing symptoms in perimenopausal and postmenopausal women, yet data on short-term hormone therapy effectiveness in Vietnam remain limited. This prospective study evaluated 85 women treated with 0.05 mg/day transdermal 17β-estradiol and 100 mg/day oral micronized progesterone for one month at Hung Vuong Hospital. Hot flash severity, measured using the Menopause Rating Scale, significantly declined post-treatment (p < 0.001). Perimenopausal women experienced greater improvement than postmenopausal counterparts (mean score reduction: 2.29 vs. 1.83). Multivariable analysis identified postmenopausal status as a negative predictor (β = -0.51; p = 0.007), while residing in Ho Chi Minh City (β = 0.38; p = 0.010) and prior hysterectomy or oophorectomy (β = 0.64; p = 0.047) were associated with better outcomes. These findings support the short-term efficacy of combined hormone therapy and highlight the importance of considering menopausal stage and demographic factors in tailoring treatment strategies for Vietnamese women.

Article Details

Keywords

Hot flashes, Menopause, Transdermal estradiol, Progesterone

References

1. Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women’s lives. The American Journal of Medicine. 2005; 118(12): 14-24. doi:10.1016/j.amjmed.2005.09.031.
2. Nappi RE, Kroll R, Siddiqui E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause. 2021; 28(8): 875-882. doi:10.1097/GME.0000000000001793.
3. Writing Group For The Women’s Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative Randomized Controlled Trial. JAMA: The Journal of the American Medical Association. 2002; 288(3): 321-333. doi:10.1001/jama.288.3.321.
4. Newson LR, Lass A. Effectiveness of transdermal oestradiol and natural micronised progesterone for menopausal symptoms. Br J Gen Pract. 2018; 68(675): 499-500. doi:10.3399/bjgp18X699353.
5. Sarri G, Pedder H, Dias S, Guo Y, Lumsden M. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG. 2017; 124(10): 1514-1523. doi:10.1111/1471-0528.14619.
6. Nguyễn ĐPT, Cao NT, Nguyễn VQH. Đánh giá hiệu quả của estradiol trong điều trị rối loạn vận mạch và rối loạn tâm lý ở phụ nữ mãn kinh. Tạp chí Phụ sản. 2016; 14(3): 129-134. doi:10.46755/vjog.2016.3.762.
7. National Institute for Health and Care Excellence. Menopause: diagnosis and management. presented at: NICE Guideline [NG23]. Published online 2015.
8. Heinemann LA, DoMinh T, Strelow F, Gerbsch S, Schnitker J, Schneider HP. The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study. Health Qual Life Outcomes. 2004; 2(1): 67. doi:10.1186/1477-7525-2-67.
9. Nguyen HTM, Tran NTT, Nguyen HM, Do DV. Reliability and validity of the Vietnamese menopause rating scale. MedPharmRes. 2023; 7(4): 48-55. doi:10.32895/ump.mpr.7.4.6.
10. Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-150. doi:10.3109/13697137.2015.1129166.
11. Thai Phuc T. Some Symptoms of Dysfunction and Quality of Life Among Menopausal Women: A Community-Based Study in A Rural Area of Thai Binh. Trends in Nursing and Health Care Research. 2022; 2(1). doi:10.53902/TNHCR.2022.02.000512.
12. Archer DF. Percutaneous 17β-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women: Menopause. 2003; 10(6): 516-521. doi:10.1097/01.GME.0000070526.74726.8A.
13. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Gynaecology and Fertility Group, ed. Cochrane Database of Systematic Reviews. 2004; 2009(1). doi:10.1002/14651858.CD002978.pub2.
14. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017; 24(7): 728-753. doi:10.1097/GME.0000000000000921.